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The TNF receptor family member OX40 promotes activation and proliferation of T cells, which 36 
fuels present attempts to modulate this immune checkpoint to reinforce anti-tumor immunity. 37 
Besides T cells, NK cells are a second cytotoxic lymphocyte subset that plays an important role 38 
in anti-tumor immunity, particularly in leukemia, and multiple approaches to utilize the potential 39 
of these cells for cancer treatment, like adoptive transfer of ex vivo expanded polyclonal NK cells 40 
(pNKC), are presently being clinically evaluated. So far, it is unknown whether and how OX40 41 
and its ligand (OX40L) influence NK cell function and anti-leukemia reactivity. In this study we 42 
report that OX40 is expressed on leukemic blasts in a substantial percentage of patients with 43 
acute myeloid leukemia (AML) and, as revealed upon stimulation with agonistic OX40 44 
antibodies, can mediate proliferation and release of cytokines that act as growth and survival 45 
factors for the leukemic cells. Moreover, we demonstrate that pNKC differentially express OX40L 46 
depending on the protocol used for generation. OX40L signaling was found to promote NK cell 47 
activation, cytokine production and cytotoxicity, and disruption of OX40-OX40L interaction 48 
impaired pNKC reactivity against primary AML cells. Together, our data identify a yet unknown 49 
involvement of OX40/OX40L in disease pathophysiology of AML and in NK cell 50 
immunosurveillance. Our findings indicate that effects of this molecule system in other immune 51 
cell subsets and also malignant cells should be taken into account when developing OX40-52 




Modulation of immune checkpoints has become a mainstay in oncological treatment. Besides 55 
already approved approaches that block inhibitory molecules like CTLA-4 or PD-1, agonistic 56 
antibodies that trigger activating receptors on T cells are presently being developed, one of them 57 
being OX40.1-4 This member of the TNF receptor (TNFR) superfamily is upregulated on effector 58 
T cells after activation and promotes their differentiation, proliferation/expansion and longterm 59 
survival while inhibiting the suppressive activity of regulatory T cells.5,6 In cancer patients, the 60 
frequency of tumor-infiltrating OX40-positive T cells correlates with survival, and application of 61 
OX40 agonists, alone or in combination with other checkpoint modulators, stimulated the 62 
cytolytic activity of T cells and caused tumor regression in preclinical models.7-11 First evidence 63 
from early clinical trials, of which most are presently ongoing, indicates that OX40 stimulation is 64 
also effective in cancer patients (e.g., Curti et al.12, Linch et al.3). 65 
Besides T cells which are components of adaptive immunity, NK cells as the major cytotoxic 66 
lymphocyte subset of the innate immune system also play an important role in tumor 67 
immunosurveillance, particularly in hematological malignancies. This is supported by 68 
observations that NK cell counts and activity are reduced in patients with leukemia and that 69 
activity levels of autologous NK cells are associated with survival of leukemia patients.13-15 Their 70 
prominent role especially in acute myeloid leukemia (AML) is highlighted by studies on 71 
haploidentical stem cell transplantation (SCT), where the resulting KIR mismatch seems to be 72 
associated with pronounced Graft versus Leukemia reaction and improved clinical outcome.16 73 
Besides their role in SCT, multiple approaches presently aim to utilize adoptive transfer of 74 
allogeneic/KIR-mismatched NK cells for cancer treatment.17 75 
Beyond KIR, signals mediated by multiple other activating and inhibitory receptors determine 76 
whether NK cell responses against tumor cells are initiated or not. This comprises various 77 
members of the TNF/TNFR family which influence NK cell reactivity upon interaction with their 78 
counterparts expressed e.g. on leukemic cells.18,19 Notably, OX40L was reported to be 79 
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upregulated on NK cells following activation,20 and its counterpart OX40 was found to be 80 
expressed by T cell-derived leukemia cells.21 However, the influence of the OX40/OX40L system 81 
on NK function or its role in AML is so far unknown. Here we report, among others, that AML 82 
cells express OX40, and exposure to an agonistic OX40 antibody (mAb) promotes leukemia cell 83 
proliferation and release of cytokines that influence growth and survival of the malignant 84 
cells.22,23 Moreover, we found that OX40L is differentially expressed on polyclonal NK cells 85 
(pNKC) generated for adoptive transfer depending on the particular protocol utilized, and that 86 
OX40L (reverse) signaling alters NK cell function including their reactivity against AML cells.  87 
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Material and Methods  88 
Cells 89 
Peripheral blood mononuclear cells (PBMC) and bone marrow (BM) cells of patients and healthy 90 
donors were isolated by density gradient centrifugation after informed consent in accordance 91 
with the Helsinki protocol. The study was conducted according to the guidelines of the local 92 
ethics committee.  93 
pNKC were generated according to standard protocols by incubating non-plastic-adherent 94 
PBMC with irradiated RPMI8866 (pNKC-8866) or K562-mb15-41BBL feeder cells obtained from 95 
St. Jude´s Children´s Research Hospital (pNKC-SJ) as previously described.24,25 Functional 96 
experiments were performed when purity of NK cells (CD56+CD3-) was above 90% as 97 
determined by flow cytometry. In addition, K562 cells were transfected using the vector pcDNA3 98 
containing the open reading frame of human 4-1BBL (K562-4-1BBL) or empty vector as control 99 
(K562-mock) as described previously.25  100 
U937 cells were transfected using the vector pcDNA3 containing the open reading frame of 101 
human OX40 (U937-OX40) or empty vector as control (mock) and cultured as described 102 
previously.25  103 
The OX40:Fas reporter cells (Jurkat-JOM2) and their use in cytotoxic assays were previously 104 
described.26 105 
Isolation of highly pure (purity >95%) NK cells from pNKC and AML cells from patient PBMC 106 
was performed by immunomagnetic separation using the NK cell isolation kit and negative 107 
selection using microbeads CD3, CD14, CD19 and CD56 from Miltenyi Biotec (Bergisch 108 
Gladbach, Germany) according to the manufacturers instructions.  109 
 110 
Reagents 111 
OX40 mAb BerAct35, OX40L mAb ANC10G1 and mouse IgG1 isotype control were from Ancell 112 
Corporation (Bayport, MN) and BD Biosciences (Heidelberg, Germany), respectively. OX40L 113 
6 
 
mAb lk-1 and 11C3.1 were from BD Biosciences and Biolegend (San Diego, CA), respectively. 114 
All fluorescence conjugates were from BD Biosciences, secondary goat anti–mouse-PE was 115 
from Dako (BIOZOL, Eching, Germany). Fusion proteins consisting of human OX40 with a 116 
murine (OX40-Fc) and human (OX40-huFc) Fc-part were from R&D Systems (Minneapolis, MN) 117 
and Ancell, respectively. RhIL-2 was from ImmunoTools (Friesoythe, Germany). 118 
In addition, antibodies against human OX40 were raised by immunization of C57BL/6 mice by 119 
repeated injection of 20x106 OX40-transfected CHO cells. Then spleen cells were fused with 120 
SP2/0-Ag14 cells, and hybridoma cells secreting OX40 mAbs were cloned by limiting dilution. 121 
mAbs were purified from hybridoma supernatants using Protein A Agarose columns (GE 122 
Healthcare, Muenchen, Germany). F(ab’)2 fragments were generated using previously described 123 
standard protocols.27 124 
 125 
Flow cytometry  126 
Analysis of OX40 and OX40L surface expression was performed using specific mAb or isotype 127 
control followed by anti–mouse-PE using a BD FACSCanto™ II.  128 
Leukemic cells in patient samples were selected by FSC/SSC and employing the surface 129 
markers CD33/CD34/CD14/CD117 based on the individual immunophenotype defined upon 130 
routine diagnosis. Specific fluorescence indices (SFI) were calculated by dividing median 131 
fluorescences obtained with specific mAb by median fluorescences obtained with isotype 132 
control. Expression was considered positive in case of SFI≥1.5. Intracellular staining was 133 
performed using the Fixation/Permeabilization Solution Kit with BD GolgiStop™ from BD 134 
Biosciences according to manufacturer’s instructions. 135 
 136 
PCR analysis  137 
OX40 primers were 5’-TGTAACCTCAGAAGTGGGAGTG-3’ and  138 
5’-GGTCCCTGTCCTCACAGATTG-3’. 18S rRNA primers were  139 
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5’-CGGCTACCACATCCAAGGAA-3’ and 5’-GCTGGAATTACCGCGGCT-3’. OX40L primers 140 
were 5’-CTGCTCCTGTGCTTCACCTAC-3’ and 5’-TCCAGGGAGGTATTGTCAGTG-3’. GAPDH 141 
primers were 5’-AGCCACATCGCTCAGACAC-3’ and 5’-GCCCAATACGACCAAATCC-3’. 142 
Reverse transcriptase–polymerase chain reaction (RT-PCR) was performed as described 143 
previously.18 144 
For quantitative PCR, total RNA was isolated using the High Pure RNA Isolation Kit (Roche, 145 
Mannheim, Germany) and transcribed into cDNA using qScript XLT cDNA SuperMix (Quanta 146 
Biosciences, Gaithersburg, MD) according to the manufacturer's instructions. Amplification of 147 
OX40 cDNA was performed using PerfeCTa SYBR Green FastMix (Quanta Biosciences) on a 148 
LightCycler 480 instrument. Primer assays (QuantiTect Primer Assay, Qiagen, Hilden, Germany) 149 
for OX40 and 18S ribosomal RNA were used according to the manufacturer's instructions. 150 
Relative mRNA expression was calculated by the ΔΔ cycle-threshold (Ct) method. 151 
 152 
Cytotoxicity assays  153 
Cytotoxicity of NK cells against primary leukemia cells and U937-transfectants was determined 154 
by 51chromium release assays after 4h or 24h as previously described.28 155 
 156 
Determination of cytokine levels and metabolic activity  157 
Cytokine determination was performed by ELISA according to manufacturer’s instructions using 158 
OptEIA sets from BD Pharmingen or DuoSet ELISA development systems from R&D Systems. 159 
Metabolic activity was measured using the cell proliferation reagent WST-1 set (Roche) 160 




OX40L is differentially expressed on pNKC 163 
As OX40L can be upregulated on NK cells upon activation and ex vivo-preactivated pNKC are 164 
being evaluated for cancer treatment,17,20 we characterized OX40L expression in pNKC 165 
generated according to two differing standard protocols (pNKC-886625 and pNKC-SJ24). RT-PCR 166 
revealed substantial and similar OX40L mRNA levels in both pNKC preparations (Fig. 1A). Next 167 
we employed various commercially available OX40L mAb to study surface expression using NK-168 
92 cells, which do not express OX40L mRNA (Fig. 1A) as negative control and OX40-Fc fusion 169 
protein to ascertain specificity. Comparative FACS analyses revealed that only mAb ANC10G1 170 
can reliably be used to determine OX40L expression, while the other two mAbs (but not OX40-171 
Fc) unspecifically bound to NK-92 cells as exemplified in Fig. 1B. While resting NK cells of 172 
healthy donors were never found positive for surface OX40L and pNKC-8866 displayed only low 173 
or no relevant levels, pNKC-SJ displayed substantial and significantly higher OX40L surface 174 
expression. Notably, this difference between pNKC-8866 and pNKC-SJ held true for 175 
preparations generated with PBMC of the same or independent donors and despite the 176 
considerable variation among individual donors (Fig. 1C, P<0.05, Mann-Whitney test and data 177 
not shown). Expression in pNKC-SJ peaked after 4-6 days of culture and declined thereafter but 178 
OX40L was still profoundly expressed at the time point when the pNKC are usually used for 179 
functional experiments and clinical application (usually beginning day 8 of culture) by us and 180 
others.29 In some cases a slight upregulation of OX40L was observed early during culture of 181 
pNKC-8866, but expression levels always were clearly lower than that of pNKC-SJ and OX40L 182 
was never detectable after day 9 (Fig. 1D). In line with previous findings,20 activation of NK cells 183 
with IL-2 alone was not sufficient for induction of OX40L; upregulation rather was dependent on 184 
4-1BB stimulation as revealed by coculture experiments involving K562-41BBL and mock 185 




Signaling via OX40L modulates NK cell reactivity 188 
In addition to acting as a ligand for OX40, OX40L can, like several other TNF family members, 189 
itself transduce signals into the ligand-bearing cell.30 To determine whether and how such 190 
reverse signaling via OX40L affects NK cells, we cultured pNKC on immobilized OX40-Fc or Fc-191 
control to allow for OX40L crosslinking in the absence of a second, OX40-expressing (target) 192 
cell population. FACS analysis of the activation markers CD69 and NKp44 revealed a significant 193 
(both P<0.05; Mann-Whitney test) upregulation on pNKC-SJ following OX40L signaling, while 194 
the OX40L-negative pNKC-8866 were not affected (Fig. 2A). In addition, triggering OX40L also 195 
led to a significant (P<0.001, Mann-Whitney test) induction of IFN- release by OX40L-positive 196 
but not -negative pNKC, which again confirmed that signals were mediated via OX40L. The 197 
effect of OX40L-signaling was observed both in the absence and presence of IL-2, the latter 198 
serving to mimic a generally augmented state, which indicates that OX40L signaling may further 199 
enhance the activity of activated NK cells (Fig. 2B). 200 
To determine whether OX40L also affects NK lysis, we next transfected U937 cells to express 201 
high levels of OX40 (U937-OX40) and generated mock-transfectants (U937-mock) as control. 202 
When the transfectants were employed in cytotoxicity assays, we observed significantly (P<0.05, 203 
Student’s t-test) higher lysis rates for the OX40-positive targets (Fig. 2C). Next we aimed to 204 
disrupt receptor-ligand engagement in this experimental setting to confirm that OX40-OX40L 205 
interaction enhances NK lysis of target cells. We reasoned that for this purpose a blocking OX40 206 
mAb would be ideally suited, because thereby (in contrast to using OX40L mAb) binding to and 207 
potential induction of signaling in NK cells would be avoided. In addition, to exclude potential Fc-208 
mediated effects/ADCC after mAb binding to OX40 on target cells, we wanted to utilize F(ab’)2-209 
fragments. As no OX40 mAb with distinct blocking capacity was commercially available, we 210 
generated mouse OX40 mAb as described in the methods section and, after production and 211 
definition of specificity, employed these in cross-competition experiments using OX40-huFc. As 212 
depicted in Fig. 2D, our mAb clones M-OX2 and M-OX17 specifically and comparably bound to 213 
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the U937-OX40 transfectants, but only M-OX2 clearly disrupted OX40-OX40L interaction as 214 
revealed by reduced binding of OX40-huFc to OX40L on pNKC-SJ. We then produced F(ab’)2-215 
fragments of M-OX2 according to standard protocols27 and employed these in cytotoxicity 216 
assays with pNKC-SJ and U937-transfectants. While no effect on NK lysis of mock-transfectants 217 
was observed, blocking OX40 significantly (P<0.05, Student’s t-test) decreased the per se 218 
higher cytotoxicity observed with the OX40-transfectants, which confirmed the stimulatory effect 219 
of OX40-OX40L interaction on NK cell reactivity (Fig. 2E).  220 
 221 
Expression of OX40 on AML cells 222 
Next we employed FACS analysis to study whether OX40 is expressed on the surface of 223 
leukemic cells using a total of 111 different AML patient samples and also CD34+ progenitor 224 
cells obtained from peripheral blood and BM of healthy donors. Leukemic blasts within PBMC 225 
were selected as described in the methods section. The clinical characteristics of each patient 226 
and individual SFI levels are given in Table 1. While no surface expression was observed on 227 
healthy CD34+ cells, their malignant counterparts displayed relevant OX40 expression in a 228 
substantial proportion of AML cases (SFI≥1.5, n=60 (54%); SFI≥2.0, n=41 (37%) (Fig. 3A, B). 229 
Interestingly, CD34+ cells from patients with chronic myeloid leukemia (CML, n=10) and 230 
myelodysplastic syndrome (MDS, n=6) showed no relevant OX40 expression (suppl. Fig. 1A). In 231 
AML, OX40 expression was significantly associated with the t(15;17) translocation (PML/RARA) 232 
and FLT3-ITD mutation (both p<0.05, Mann-Whitney-U-test), whereas no association with other 233 
genetic abnormalities, risk according to the ELN classification, FAB classification, disease 234 
etiology (i.e. secondary AML from MDS) or clinical parameters like extent of BM fibrosis, 235 
treatment response or survival was observed (table 2 and data not shown). OX40 expression by 236 
AML cells was also confirmed on mRNA level using RT-PCR: Amplicons of OX40 were detected 237 
in all 8 investigated samples of patients with at least 80% blast count (Fig. 3C). Notably, this also 238 
comprised samples of three patients without detectable surface expression on leukemic cells. 239 
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Very low or no OX40 mRNA was detected in the CD34-enriched BM cells of healthy donors (Fig. 240 
3D). Quantitative PCR revealed significantly (P<0.05, Mann-Whitney test) lower mRNA levels in 241 
healthy CD34+ BM cell samples and surface-negative compared to surface-positive AML 242 
samples (Fig. 3E). Next we cultured primary AML cells in the presence of OX40L, G-CSF, GM-243 
CSF, IFN-, TNF, IL-6, IL-8 and IL10 for various times (6h, 24h and 48h) and then analysed 244 
OX40 expression by FACS using an (non-competing) OX40 mAb. Interestingly, we found that 245 
TNF significantly induced OX40 expression beginning already after 6h with a peak at 24h, while 246 
none of the other factors had any effect (Fig. 3F and data not shown). 247 
 248 
OX40 can induce cytokine release and promote proliferation of AML cells 249 
To elucidate the role of OX40 on AML cells we functionally characterized our newly generated 250 
OX40 mAb using a reporter cell assays in which Jurkat-JOM2 cells expressing a human OX40-251 
Fas chimeric receptor are killed upon engagement of the OX40 portion of the receptor.26 OX40 252 
mAb clone M-OX17 killed these reporter cells in a dose dependent manner, indicating that it has 253 
agonist activity (Fig. 4A). The same mAb also stimulated a robust IL-8 production in U937-OX40 254 
transfectants, but not in mock controls, which further confirmed its specific stimulatory property 255 
(Fig. 4B).  256 
Next we aimed to determine whether OX40 on leukemic cells of AML patients was functional. No 257 
clear association of constitutive OX40 expression with the basal release of the cytokines TNF, 258 
IL-10, IL-6 and IL-8 in vitro, the extent of fibrosis in BM samples, metabolic activity/proliferation 259 
of leukemic cells or apoptosis/death in vitro was observed (suppl. Fig. 2 and data not shown). 260 
However, M-OX17-induced OX40 signaling resulted in a significant (all P<0.05, Wilcoxon signed 261 
rank test) induction of TNF, IL-10, IL-6 and IL-8 by OX40-positive AML cells (both in cases with 262 
de novo and secondary AML from MDS), while no effects were observed with OX40-negative 263 
leukemic cells (Fig. 4C, suppl. Fig. 3A and data not shown). Notably, we observed substantial 264 
inter-individual differences concerning the cytokine release of AML cells upon OX40 signaling. 265 
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None of the 19 investigated samples released all four cytokines. Release of TNF, IL-10, IL-6 and 266 
IL-8 was observed with 15, 10, 15, 3 of the 19 samples, respectively (Fig. 4D). Analysis of 267 
intracellular IL-8 and TNF levels by FACS and gating for CD33+/CD19-/CD3- cells served to 268 
ascertain that in fact the leukemic cells among patient-PBMC produced the respective cytokines 269 
upon OX40-stimulation (Fig. 4E). WST-1 assays then further revealed that OX40 signaling can 270 
also significantly (P<0.05, Wilcoxon signed rank test) enhance AML cell proliferation/viability: in 271 
OX40-positive AML patient samples, 8 (53%) and 5 (33%) out of 15 investigated patients 272 
responded to OX40 stimulation with a 1.5-fold and 2-fold increase, respectively, while no effect 273 
was observed with OX40-negative samples as controls (Fig. 4F, suppl. Fig. 3B and data not 274 
shown). 275 
 276 
OX40-OX40L interaction enhances NK cell cytotoxicity in response to AML cells 277 
Finally we aimed to determine the outcome of OX40-OX40L interaction for NK cell anti-leukemia 278 
reactivity. As a first step, we studied the frequency and activation state of NK cells within AML 279 
patients with different OX40 expression levels on leukemic blasts, which however did not reveal 280 
a clear correlation (suppl. Fig. 4). This can be attributed to the fact that NK cell reactivity is 281 
influenced by a multitude of activating and inhibitory receptors as well as cytokines and other 282 
immune cell subsets far beyond the newly identified OX40/OX40L molecule 283 
system.{Handgretinger, 2016 #11} Accordingly we next aimed to delineate the specific role of 284 
this molecule system by employing our blocking OX40-F(ab’)2-fragments in long term (24h) 285 
chromium release assays with OX40L-positive pNKC-SJ of 9 different healthy donors and OX40-286 
positive primary AML cells from 8 different patients (at least 80% blast count). Blocking OX40 287 
significantly (P<0.0001, Wilcoxon signed rank test) decreased lysis of primary AML cells, while 288 
the isotype control had no relevant effect (Fig. 5A, B). To further exclude a potential influence of 289 
other immune effector cells remaining in AML patient samples or the pNKC preparations, we 290 
conducted lysis assays using primary AML samples after MACS-depletion of 291 
13 
 
CD3/CD14/CD19/CD56 cells as targets with highly purified NK cells obtained by MACS-isolation 292 
from bulk pNKC-SJ as effectors. Again we found that blocking OX40-OX40L interaction reduced 293 
AML cell lysis, which confirmed the stimulatory role of this molecule system in AML-NK cell 294 




The therapeutic inhibition of immune checkpoints to reinforce anti-tumor immunity of T cells has 297 
meanwhile become a mainstay of cancer treatment. However, many patients do not benefit from 298 
the presently available checkpoint blockers that target CTLA-4 and PD-1/PD-L1, or for limited 299 
time only.2 New strategies are thus needed and are presently being developed to better exploit 300 
the immune system’s potential to combat malignant disease. Novel approaches beyond blocking 301 
immune-inhibitory molecules comprise, among others, therapeutic stimulation of activating 302 
immune receptors on T cells, but also ex vivo manipulation/expansion and subsequent transfer 303 
of cytotoxic lymphocytes, like chimeric antigen receptor (CAR) T cells31 or pNKC.29 304 
The TNFR family member OX40 is a prominent example of an activating receptor that can 305 
reinforce T cell anti-tumor-reactivity in the sense of a “stimulatory” immune checkpoint. 306 
Preclinical studies with agonistic mAb revealed that the ability of OX40 to stimulate T cells is 307 
comparable to e.g. CTLA-4 blockade.12 Due to its profound ability to sustain T cell 308 
proliferation/survival, OX40 is also frequently used in the costimulatory signaling domain of 309 
CAR.32,33 The latter confines the effects of OX40 activation to the transfected T cells, while 310 
systemic application of agonistic mAb may also affect other cellular components of the immune 311 
system and the many non-immune cells that express OX40.4-6 Our results obtained by FACS 312 
analysis of 111 primary patient demonstrate that AML cells (but not CD34+ cells of healthy 313 
donors or patients with MDS or CML) express OX40 on the cell surface in a substantial 314 
proportion of cases. Notably, OX40 mRNA expression was also observed in AML samples 315 
without relevant surface expression. While contamination with OX40-expressing healthy cells 316 
may have influenced the respective PCR results, it appears rather likely that regulatory or 317 
mutational blockade of surface expression by posttranscriptional and/or posttranslational 318 
mechanisms may have contributed to the same. This may comprise, alike reported for many 319 
other TNF/TNFR members, cell surface shedding and release in soluble form, which is 320 
supported by reports on the presence of soluble OX40 in sera of patients with malignant and 321 
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autoimmune diseases.34-37 Our finding that OX40 expression can be upregulated by exposure of 322 
AML cells to TNF indicates that environmental stimuli in the micromilieu may affect OX40 323 
expression via these or other yet unidentified mechanisms.  324 
Functional analyses using newly generated mAb with defined specificity and agonistic property 325 
revealed that OX40 signaling can induce the release of cytokines that act as autocrine/paracrine 326 
growth and survival factors in AML and are associated with development and progression of the 327 
disease.22,23 Notably, OX40 signaling did not always induce release of the same cytokines. 328 
Rather, we found distinct patterns of cytokine release upon OX40 signaling, and whereas TNF 329 
and IL-6 were released in more than 70% of the investigated cases, IL-10 and IL-8 were only 330 
released by about half and less than 20% of the patient samples, respectively. With none of the 331 
AML samples, release of all four cytokines was observed, but all investigated OX40-positive 332 
AML patient samples responded to OX40 signaling by release of at least one of the cytokines. 333 
OX40 may thus (variably) contribute to the cytokine milieu associated with AML. Furthermore, 334 
alike in T cells, OX40 signaling enhanced viability/metabolic activity in a substantial proportion of 335 
the AML cases. It seems thus possible that OX40 confers a survival benefit for leukemic cells, 336 
e.g. upon interaction with OX40L bearing immune or bystander cells. This is in line with 337 
increasing evidence regarding the important role of the immune and stromal microenvironment 338 
in malignancies in general, which also holds true for AML.38 Moreover, these findings support 339 
our above-mentioned line of argument regarding potential unexpected consequences of a 340 
therapeutic application of “untargeted” agonistic OX40 mAb, and it is noteworthy that other 341 
investigators reported on OX40 expression (without analyzing functionality) on cancer cells of 342 
various origins beyond AML.39 Another layer of complexity when applying OX40 mAb is added 343 
by the issue of whether and how mAb-binding to OX40 affects interaction with cells that express 344 
its cognate ligand. This is of particular relevance because OX40-OX40L interaction can lead to 345 
transduction of bidirectional signals, i.e. into the receptor and the ligand-bearing cell, a 346 
characteristic feature of many ligands of the TNF family.30,40 Besides healthy tissues like 347 
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endothelial cells, antigen-presenting cells including B cells, monocytes/dendritic cells express 348 
OX40L, and various cellular functions of these cells are affected by OX40L "reverse 349 
signaling",30,41-43 which may also occur upon their interaction with OX40-expressing AML cells.  350 
Notably, Zingoni and colleagues reported that also NK cells, which play an important role in the 351 
immune surveillance particularly of leukemia,44 express OX40L following activation and stimulate 352 
OX40-expressing T cells via this molecule system.20 Despite the fact that presently multiple 353 
approaches evaluate the clinical efficacy of ex vivo expanded/activated NK cells upon adoptive 354 
transfer,17 the expression and function of OX40L by such cell preparations has so far not been 355 
analyzed. When we studied OX40L expression on pNKC generated as described in the work of 356 
Zingoni et al.20 (pNKC-8866) or generated according to a protocol employed for large-scale 357 
clinical grade expansion (pNKC-SJ),24,29,45 we observed no or very low OX40L expression on the 358 
first which are generated by culture with RPMI8866 feeder cells in the presence of IL-2. In 359 
contrast, OX40L was highly expressed on pNKC-SJ that are expanded in the presence of K562 360 
cells transfected with 4-1BBL and membrane-bound IL-15 as well as soluble IL-2. In line with the 361 
findings of Zingoni et al.20, cytokine activation of NK cells alone was not sufficient to induce 362 
OX40L expression, and additional expression of 4-1BBL as revealed by analyses involving 363 
transfectants and transwell settings was required. Notably, in a clinical study with pediatric solid 364 
tumors that received IL-15/4-1BBL-activated NK cells after allogeneic SCT, acute GVHD was 365 
observed despite the fact that the T cell dose in the grafts was below the threshold usually 366 
required for GVHD in this setting.46 The mechanism underlying this observation remained 367 
unclear, but it is tempting to speculate that the above described ability of NK cells to stimulate T 368 
cells via OX40-OX40L interaction may have contributed to the same. This hypothesis is 369 
supported by observations in mouse models of GVHD, where OX40 signals in effector T cells 370 
play a crucial pathophysiological role.47-49 371 
When we analyzed how OX40L reverse signaling affected NK cells, we found that OX40L-372 
induced activation and production of IFN-a cytokine which participates in cancer elimination by 373 
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inhibiting cellular proliferation and angiogenesis, promoting apoptosis, and stimulating the 374 
adaptive immune system.50 Analyses with OX40-transfectants revealed that OX40-OX40L 375 
interaction also enhanced NK lysis of target cells. This was further confirmed in experiments 376 
using F(ab’)2-fragments of a blocking OX40-antibody, which substantially reduced NK cell killing. 377 
Notably, 17 independent experiments with primary OX40-expressing AML cells and OX40L-378 
positive pNKC of different patients/donors also clearly revealed that disruption of OX40-OX40L 379 
interaction reduces target cell lysis despite the observed substantial donor variability. The latter 380 
might be due to differing OX40 and OX40L-expression levels (or differences in other 381 
immunoregulatory molecules that influence NK function) on AML cells and pNKC, respectively. 382 
Thus, even when the intracellular pathways and molecular mechanisms that mediate OX40L 383 
signaling in NK cells remain so far unclear and require further elucidation, our results clearly 384 
demonstrate that OX40L enhances the reactivity of NK cells. 385 
Taken together, the results presented in this study unravel the yet unknown expression of OX40 386 
in AML and point to its involvement in disease pathophysiology. In addition, we report on the 387 
consequences of reverse signaling via its counterpart OX40L for NK cells including their anti-388 
leukemia reactivity. A limitation of our study is that we were not able to demonstrate expression 389 
of OX40L on NK cells of AML patients directly ex vivo, but it needs to be considered that all 390 
OX40L antibodies available for FACS analysis compete with OX40 for OX40L binding. NK cell-391 
expressed OX40L could thus be masked e.g. by soluble OX40.{Taylor, 2001 #1450;Komura, 392 
2008 #19} Moreover, OX40L can be released by shedding, which might particularly occur after 393 
binding to its AML-expressed counterpart. So far, the exact reason for our failure to detect 394 
OX40L on NK cells in our ex vivo analyses remains unclear. In addition, it still remains to be 395 
determined whether and how OX40/OX40L interactions endogenously affect AML cells or NK 396 
cells, as the latter themselves can express OX40.  397 
Nevertheless, our findings deserve consideration with regard to potential consequences of 398 
bidirectional signaling following OX40-OX40L when designing approaches to utilize adoptive 399 
18 
 
transfer of ex vivo expanded pNKC. They also may be of relevance for therapeutic strategies 400 
aiming for checkpoint stimulation by agonistic OX40 mAbs, as they provide further evidence that 401 
OX40 can affect multiple cell types beyond T cells including malignant cells, and the effects of 402 
OX40 agonists may thus be more complex than anticipated: the treatment may also (i) directly 403 
influence cellular properties of the malignant cells, (ii) their interaction with the 404 
microenvironment, (iii) other OX40-expressing immune cells (including NK cells), and, in case of 405 
blocking properties of the applied mAb, (iv) reactivity of other OX40L-expressing immune cells in 406 
general and NK cell immunosurveillance in particular. Thus, additional work is warranted to fully 407 
unravel the complex role of the OX40/OX40L molecule system, which in turn may help to fully 408 
exploit the potential of OX40 stimulation for cancer immunotherapy. 409 
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Figure legends 553 
Figure 1. OX40L expression on human NK cells.  554 
pNKC were generated using standard protocols (comprising medium containing 25U/ml IL-2) 555 
with either RPMI 8866 (pNKC-8866) or K562-mb15-41BBL (pNKC-SJ) as feeder cells. NK cells 556 
within PBMC of healthy donors (HD-NKC, selected by counterstaining for CD56+CD3-) and NK-557 
92 cells served as controls. 558 
(A) OX40L mRNA expression in pNKC-8866 and pNKC-SJ generated with PBMC of three 559 
different donors and NK-92 cells was determined on day 8 by RT-PCR of equal mRNA levels 560 
with 18S rRNA or GAPDH serving as control.  561 
(B) OX40L surface expression was analyzed on day 8 by FACS using OX40-Fc or the anti-562 
OX40L mAb clones ANC10G1, ik-1, 11C3.1 (shaded peaks) and their respective controls (open 563 
peaks) followed, in case of unlabeled antibodies, by secondary PE-conjugates.  564 
(C) SFI levels of OX40L surface expression as obtained by analysis of pNKC-SJ, pNKC-8866 565 
and HD-NKC (obtained from seven independent healthy donors each) on day 7 or 8 using mAb 566 
ANC10G1 as described above. 567 
(D) SFI levels of OX40L surface expression on NK cells were determined at the indicated time 568 
points of coculture of PBMC with RPMI8866 or K562-mb15-41BBL as described in (C). 569 
(E) To unravel the molecular mechanism involved in OX40L upregulation, PBMC of healthy 570 
donors were cultured and analysed by FACS as described above on day 7 after culture with 571 
K562-mb15-41BBL (separated by a transwell insert (TW) to prevent cell contact where 572 
indicated), K562-mock or K562-4-1BBL as indicated. 573 
Data of one representative experiment of a total of three with similar results are shown. 574 
*Statistically significant differences, P<0.05. 575 
 576 
Figure 2. OX40L stimulates reactivity of human NK cells.  577 
(A,B) OX40L-negative pNKC-8866 and OX40L-positive pNKC-SJ were cultured alone, on 578 
26 
 
immobilized OX40-Fc or isotype control for 24 hours. Where indicated, 25 U/ml IL-2 was added 579 
during culture. Exemplary results (left) and combined data of at least 6 experiments with pNKC-580 
SJ of independent donors after setting results with pNKC alone to 1 for normalization to account 581 
for donor variability (right) are shown. Horizontal bars represent the mean of the results within 582 
each culture condition. (A) Expression of CD69 and NKp44 was analyzed by FACS of 583 
CD56+CD3- pNKC-8866 (upper two panels) or pNKC-SJ (lower two panels) using specific 584 
fluorescence conjugates and isotype control. (B) IFN- levels in culture supernatants were 585 
determined by ELISA.  586 
(C) Expression of OX40 on transfectants (U937-OX40) and mock controls (U937-mock) was 587 
ascertained by FACS (left panels; shaded peaks, OX40 mAb; open peaks, isotype control) prior 588 
to use in 4-hour 51chromium release assays with pNKC-SJ (right panel). Exemplary results of 589 
one experiment out of five with similar results are shown. 590 
(D) Upper panels: U937-OX40 and U937-mock transfectants were analyzed by FACS using the 591 
OX40-mAbs M-OX17 and M-OX2 followed by secondary PE-conjugate. Shaded peaks, specific 592 
mAb; open peaks, isotype control. Lower panels: The OX40 mAbs M-OX17 and M-OX2 or 593 
isotype control (10µg/ml each) were preincubated with OX40-huFc or huFc-control (both at 2 594 
µg/ml) for 1h. Then pNKC-SJ cells were incubated with pretreated OX40-huFc/huFc-control 595 
followed by anti-human PE-conjugate and FACS analysis. Cross-competition and thus blocking 596 
properties of the antibodies were identified by the reduction of OX40-huFc binding to pNKC-SJ; 597 
dark grey peaks, OX40-huFc preincubated with isotype control; light grey peaks, OX40-huFc 598 
preincubated with the OX40mAb; dashed line, huFc-control. 599 
(E) U937-mock (left) or U937-OX40 (right) cells were incubated with pNKC-SJ in the presence or 600 
absence of blocking M-OX2 F(ab)2-fragments or isotype control (both at 2µg/ml) and cytotoxicity 601 
was evaluated by 4h 51chromium release assays. Data represent means of triplicates with SD, 602 
and one representative experiment of a total of at least 3 with similar results is shown.  603 
*Statistically significant differences, P<0.05. 604 
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Figure 3. OX40 is expressed on AML cells 605 
(A, B) PBMC from AML patients (upper panel) and CD34+ bone marrow and peripheral blood 606 
cells of healthy donors (middle and lower panels) were analyzed by FACS using the OX40 mAb 607 
BerAct35 (shaded peaks) and isotype control (open peaks) followed by anti-mouse PE. 608 
Exemplary (A) and combined (SFI levels, B) results with AML cells of different FAB types are 609 
shown.  610 
(C, D) PBMC of AML patients with >90% blast count (C) and CD34-enriched bone marrow cells 611 
from healthy donors (D) were analyzed by RT-PCR for OX40 mRNA; 18S rRNA served as 612 
control. 613 
(E) Quantitative real time PCR analysis of OX40 mRNA expression in PBMC samples of 614 
different OX40 surface-positive and -negative AML patients (both n=8) and CD34-enriched bone 615 
marrow cells from 7 different healthy donors.  616 
(F) PBMC of 7 AML patients were exposed to sOX40L [2 µg/ml], G-CSF, GM-CSF, IFN-, TNF, 617 
IL-6, IL-8 and IL10 [all 100 ng/ml] for 24h followed by FACS analysis with a non-competing 618 
OX40 mAb (M-OX17). 619 
*Statistically significant differences, P<0.05. 620 
 621 
Figure 4. OX40 induces cytokine release and metabolic activity of AML cells. 622 
(A) OX40: Fas reporter cells (Jurkat-JOM2) were exposed to the indicated concentrations of the 623 
anti-OX40 antibody M-OX17 or isotype control and metabolic activity was measured by WST-1 624 
assays. Representative data from one out of four experiments with similar results are shown. 625 
(B) U937-OX40 and U937-mock transfectants were cultured alone, on immobilized OX40 mAb 626 
(M-OX17) or isotype control for 24h. Then IL-8 levels in culture supernatants were determined 627 
by ELISA. Representative data from one out of four experiments with similar results are shown. 628 
(C-F) AML patient cells were cultured alone, on immobilized M-OX17 mAb or isotype control for 629 
6h (TNF and IL-8) or 24h (IL-10 and IL-6). Then (C) levels of the indicated cytokines in culture 630 
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supernatants were determined by ELISA. Data of n=19 investigated OX40+ patients (UPN 3, 4, 631 
5, 15, 27, 30, 33, 52, 55, 61, 70, 72, 76, 81, 83, 86, 94, 96, 106) are shown. Horizontal bars 632 
represent the mean of the results in each culture condition. (D) The results obtained in (C) were 633 
analyzed with regard to release of specific cytokine combinations. Positive response (+) was 634 
defined as >2-fold increase of each individual cytokine upon OX40-signaling. The percentage of 635 
samples responding with the indicated cytokine pattern is depicted. (E) Intracellular cytokine 636 
levels were analysed by FACS using specific mAbs and isotype control after 12h. AML cells 637 
within PBMC were selected as CD3-/CD19-/CD33+. Numbers in upper right quadrants indicate 638 
the percentage of IL-8+ and TNF+ AML cells. (F) Metabolic activity was measured by WST-1 639 
assays after 24h. Data of n=15 investigated OX40+ patients (UPN 3, 10, 15, 21, 25, 27, 33, 46, 640 
56, 61, 71, 72, 81, 91, 106) are shown. 641 
Horizontal bars represent the mean of the results in each culture condition. *Statistically 642 
significant differences, P<0.05. 643 
 644 
Figure 5. OX40-OX40L interaction enhances NK-cell reactivity against AML cells.  645 
(A, B) OX40L-positive pNKC-SJ were cultured with PBMC of the indicated OX40-expressing 646 
AML patients with more than 80% blast count in the presence or absence of blocking OX40-647 
F(ab’)2 or isotype control and cytotoxicity was evaluated by 24h 
51chromium release assays. In 648 
(A), three representative results are depicted, (B) shows data of 17 independent experiments at 649 
an E:T ratio of 40:1.  650 
(C) Lysis was analyzed as described above using primary AML cells after MACS-depletion of 651 
CD3/CD14/CD19/CD56 cells contained in the samples as targets and NK cells isolated by 652 
MACS-isolation from bulk pNKC-SJ as effectors. Three representative results from 9 653 
experiments with similar results are shown. 654 
*Statistically significant differences, P<0.05. 655 
 656 
UPN, uniform patient number; OX40 SFI, specific fluorescence index; FAB, French-American-British classification; F, female; M, male; PBB, 
peripheral blood blasts among nucleated cells; WBC, white blood count; Hb, hemoglobin; Plt, platelets; ELN, European LeukemiaNet; NCCN, 
National Comprehensive Cancer Network; MRC, Medical Research Council; Etiology: pAML = de novo AML, tAML = therapy related AML, 
sAML = secondary AML evolving from MDS/MPS; n.d., not determined and n.a., not available.  
Table 1. Patient characteristics and levels of cell-surface OX40 
UPN OX40 FAB Age Sex PBB [%] Diff.   Karyo WBC [G/l] Hb [g/dl] Plt [G/l] ELN NCCN  MRC Etiology 
1 1.4 M0 78 m 84 45,XY, -7,+13,-21 [28], 46,XY [2] 85 6.3 20 Adverse Poor Poor pAML 
2 1 M0 46 m 97 46, XY 60.5 7 39 Favorable Favorable Better pAML 
3 3.5 M0 49 m 83 46, XY, t(1;20)(p32;p13),del(12)(p12p13)[20] 29.2 12.9 39 Intermediate II Intermediate Intermediate sAML 
4 2.4 M1 50 f 93 46, XX 270 8 18 Intermediate I Intermediate Poor pAML 
5 5.1 M1 40 m 100 complex 81.3 10.8 51 Adverse Poor Poor pAML 
6 1.4 M1 27 m 95 46, XY 135.1 8.1 20 Favorable Favorable Better pAML 
7 1.3 M1 58 m 93 46,XY 23.9 8.2 42 Intermediate I Intermediate Intermediate n.a. 
8 1 M1 83 f 88 n.d. 128.9 7.5 15 n.a. n.a. n.a. pAML 
9 2.6 M1 67 m 78 complex 11.1 8.9 48 Adverse Poor Poor pAML 
10 2.3 M1 76 f 76 n.d. 15.6 10.7 46 n.a. n.a. n.a. pAML 
11 1.3 M1 76 m 64 complex 12180 7,3 134 Adverse Poor Poor tAML 
12 1.1 M1 61 m 63 46,XY[25] 59.4 13 69 Intermediate I Intermediate Intermediate tAML 
13 1.5 M1 68 m 86 46,XY 84.1 6.7 332 Intermediate I Poor Poor pAML 
14 1.5 M1 75 f 84 46, XX 150 10.8 174 Favorable Favorable Better pAML 
15 3.8 M1 80 f 93 n.d. 34.9 11.2 28 n.a. n.a. n.a. pAML 
16 1.5 M1 72 f 80 46 ,XX [20] 25.8 7.8 50.0 Intermediate I Intermediate Intermediate pAML 
17 2.8 M1 64 f 94 n.d. 222 9.2 44 n.a. n.a. Poor pAML 
18 1.9 M1 63 f 60 46,XX, del(9)(q22) [5]/46,XX [25] 11.3 11.3 292 Favorable Intermediate Intermediate pAML 
19 1.4 M1 50 m 98 46,XY 19.7 10.4 55 Favorable Favorable Better pAML 
20 1.4 M1 67 m 99 n.d. 67.7 9.8 23 n.a. n.a. n.a. n.a. 
21 1.5 M1 62 m 77 46,XY 45 7.1 270 Intermediate I Poor Poor pAML 
22 1.1 M1 50 f 89 46,XX, del(9)(q13,q22)[4]/ 46,XX [16] 13.8 8.8 25 Intemediate II Intermediate Intermediate pAML 
23 1 M1 44 m 75 46, XY 10.7 7.9 234 Intemediate I Poor Poor pAML 
24 2.2 M1 82 f 81 46, XX 130 10.1 127 Intermediate I Intermediate Intermediate pAML 
25 2.7 M1 47 f 98 n.d. 56.3 9.4 60 n.a. n.a. n.a. pAML 
26 0.9 M1 76 f 81 46,XX[20],  10.7 7.4 145 Favorable Favorable Better pAML 
27 6.9 M1 47 f 91 47,XX, +8 27.6 10.0 26 Intermediate II Intermediate Intermediate sAML 
28 1.1 M1 62 m 89 n.a. 18.3 12.3 18 n.a. n.a. Poor pAML 
29 1.4 M1 52 m 98 46,XY 153.3 9.2 23 Intermediate I Poor Poor pAML 
30 3.8 M1 56 f 87 46, X, t(X;12)(p11;p13)[14];46, XX [7] 4.14 8.3 111 Intermediate II Intermediate Intermediate pAML 
31 0.9 M1 68 m 93 n.d. 42.5 9.8 80 n.a. n.a. n.a. pAML 
32 1.7 M1 21 f 95 46,XX [16], 46,XX, del(9)(q13q22) [4] 84 7.1 30 Intermediate II Intermediate Poor pAML 
33 4.5 M1 41 f 92 46,XX 68.7 8.1 55 Intermediate I Poor Poor pAML 
34 1.1 M1 34 m 75 46, XY 33.3 10.2 11 Favorable Favorable Better pAML 
35 1.1 M1 38 f 60 46, XX 26 9.6 153 Intermediate I Poor Poor pAML 
36 1.2 M2 84 m 79 n.d. 115.2 7.8 107 n.a. n.a. n.a. pAML 
37 2.3 M2 30 m 53 46, XY 24.5 7.4 54 Intermediate I Poor Poor pAML 
38 1.1 M2 54 f 71 46,XX,t(8;21)(q22;q22)[21] 9 8.9 40 Favorable Favorable Better tAML 
39 1.2 M2 38 m 28 46, XY 8.8 8.7 52 Intermediate I Intermediate Intermediate sAML 
40 1.1 M2 72 m 97 complex 56.9 8.9 30 Adverse Poor Poor sAML 
41 1.4 M2 56 m 63 46, XY 8.8 9.7 311 Favorable Favorable Better pAML 
42 1.2 M2 81 m 96 n.d. 10 10 46 n.a. n.a. n.a. sAML 
43 1.2 M2 66 m 80 n.d. 27.8 10.1 49 Favorable Better Better pAML 
44 2.3 M2 29 m 70 46,XY 9.6 8.5 17 Intermediate I Poor Poor tAML 
45 1.3 M2 73 f 83 46,X,inv(X)(p22.3q13) [14]; 46,XX [6] 5 6.3 95 Intermediate II Intermediate Intermediate pAML 
46 1.8 M2 73 m 83  46,XY 33.8 8.1 80 Intermediate I Poor Poor pAML 
47 1.4 M2 68 m 96 46,XY 85.5 9.5 146 Intermediate II Intermediate Intermediate pAML 
48 1.6 M2 72 m 81 46, XY, del(17)(q11q21) [6]/47,XY,+8 [3] 46, XY [16] 78.9 6,4 47 Intermediate II Intermediate   pAML 
49 1.4 M2 51 f 43 46,XX,t(2;2)(q21;q23)[21] 35.3 9.3 51 Intermediate II Intermediate Better pAML 
50 1.2 M2 48 m 87 46,XY 36.9 7.1 66 Favorable Favorable Better pAML 
51 1.8 M2 63 m 78 46,XY 180 8 30 Favorable Favorable Better pAML 
52 1.5 M2 64 m 82 47, XY+8[16]/47,XY,+8,del(9)(q22)[1]/46,XY,del(9)(q22)[1]/46,XY[7] 338.5 8.1 19 Intermediate II Intermediate Intermediate pAML 
53 0.4 M2 58 f 92 46,XX 62 7.4 25 Intermediate I Poor Poor sAML 
54 1.1 M2 78 m 99 45, XY, -7[7], 46, XY[15]  26 9.7 36 Adverse Poor   sAML 
55 6.4 M2 68 m 84 47,XX,+11[23] 165.5 3.8 222 Intermediate II Intermediate Poor pAML 
56 1.6 M2 71 f 94 46, XX 105.4 10.4 83 Intermediate I Poor Poor pAML 
57 1.7 M2 58 m 20 complex 39.1 9.3 23 Adverse Poor Poor pAML 
58 1.3 M2 23 f 69 47,XX, +21 [2]/46,XX [23] 50 9.9 135 Intermediate II Intermediate Intermediate pAML 
59 1.1 M2 71 f 81 47, XX +11 26.1 9.4 10 Intermediate II Intermediate Intermediate sAML 
60 1.3 M2 45 m 80 complex 17.1 9.0 51 Favorable Favorable Better pAML 
61 2.5 M2 44 m 94 46,XY 138.5 10.3 57 Intermediate I Poor Poor pAML 
62 1.1 M2 45 m 94 47, XY, +8  44.4 8.7 11 Intermediate II Intermediate Poor pAML 
63 2.2 M2 45 m 94 complex 44.4 8.7 11 Adverse Poor Poor pAML 
64 1.3 M2 68 m 93 47, XY, +11 110.9 8 27 Intermediate II Intermediate Intermediate pAML 
65 0.9 M2 70 f 20 47,XX,+8,del(17)(p11-12)[5]/46,XX[20] 4 13,6 182 Adverse Poor Poor sAML 
66 5.7 M3 46 m 51 complex 23.1 13.3 25 n.a. n.a. n.a. pAML 
67 1.1 M3 67 f 94 46,XX 99 9.9 128 Intermediate II Intermediate Intermediate sAML 
68 14.3 M3 65 m 40 46, XY, t(15;17)(q22;q12)[20] 6.9 8.5 17 Favorable Favorable Better pAML 
69 5.2 M3 58 f 96 46,XX,t(15;17)(q22;q12)[20].  42.1 8.4 17 Favorable Favorable Better pAML 
70 3 M4 70 f 71 45, XX, -7 282.3 5.7 68 Adverse Poor Poor sAML 
71 1.8 M4 49 m 72 46,Y,t(X;17)(p11;p1?1),add(21)(q22)[13] 61.9 5.8 18 Adverse Poor Poor pAML 
72 2.9 M4 71 m 93 47, XY, + 11 (6) 79.7 9.9 40 Intermediate II Intermediate Intermediate pAML 
73 1.4 M4 55 m 72 46,XY 17.2 8.6 162 Favorable Favorable Better pAML 
74 9.7 M4 61 m 70 46, XY 85.4 8.5 12 Intermediate I Poor Poor pAML 
75 6.1 M4 76 f 94 46, XX, t (9;11) (q22; q23) [12]/52, XXX, +3, +6, +8 t (t;11) (q22; q23) +12, +13, +18 [13] 141 12 70 Adverse Poor Poor tAML 
76 7.3 M4 43 f 86 46, XX 63.5 9.2 178 Favorable Favorable Better pAML 
77 1.3 M4 41 f 73 complex 112.7 8.5 30 Adverse Poor Poor pAML 
78 5 M4 63 m 96 46,XY 92.3 10.5 431 Intermediate I Poor Poor pAML 
79 2.2 M4 73 f 85 46,XX (25) 52.6 7.5 48 Intermediate I Poor Poor tAML 
80 1.2 M4 71 m 75 46, XY,del(20)(q11)[6];47,idem,+11[14]; 161.1 8.6 61 Intermediate II Intermediate Intermediate sAML 
81 1.6 M4 83 f 95 46,XX add(14)(p11)[8],/46, XX[5] 155.8 11.6 144 Intermediate II Intermediate Intermediate pAML 
82 2.3 M4 78 f 39 51 ,XX,+6,+9,+9,+11 ,+13[20]  8.8 9.2 146 Adverse  Poor Poor pAML 
83 2.7 M4 64 m 22 46,XY 62.4 7.5 40 Intermediate I Poor Poor n.a. 
84 1.5 M4 36 m 78 46, XY  207.4 6.1 55 Intermediate I Poor Poor pAML 
85 2 M4 68 m 82 46, XY 148.7 9.1 134 Intermediate I Poor Poor pAML 
86 4.4 M4 67 m 75 46,XY,?dup(9)(p13p22)c 64.4 9.1 33 Intermediate II Intermediate Intermediate pAML 
87 0.6 M4 72 f 81 46,XX 26.1 8.2 70 Intermediate I Intermediate Interemdiate pAML 
88 2 M4 54 f 46 46, XX 17.2 10.6 167 Intermediate I Poor Poor pAML 
89 1 M4 57 m 68 n.d. 334 9.4 293 n.a. n.a. n.a. pAML 
90 2.2 M4 57 f 29 46,XX 17.5 8.0 117 Intermediate I Intermediate Intermediate pAML 
91 3.3 M4 56 f 64 46, XX, inv(16)(p13.1q22)[11] 56.6 10.9 99 Favorable Favorable Better pAML 
92 0.8 M5 70 m 90 46,XY 190 7.1 65 Intermediate I Intermediate Intermediate pAML 
93 1.6 M5 70 m 4 46, XY 73.6 13.2 25 Favorable Favorable Better pAML 
94 1.6 M5 26 f 18 46, XX 51 6,2 17 Favorable Favorable Better pAML 
95 7.3 M5 73 m 97 47, XY,+8[2]; 46,XY[23] 78.9 6.4 47 Intermediate II Intermediate Poor tAML 
96 28.5 M5 69 f 80 n.d. 275 7.1 47 n.a. n.a. Poor pAML 
97 1.3 M5 65 m 91 n.d. 394.2 7.9 189 n.a. n.a. n.a. sAML 
98 1.7 M5 69 m 11 n.d. 22.1 8.7 53 n.a. n.a. n.a. pAML 
99 1.1 M5 24 m 90 n.d. n.d. n.d. n.d. n.a. n.a. n.a. pAML 
100 1.3 M5 78 m 49 complex 11.7 8 13 Adverse Poor Poor pAML 
101 1.3 M5 74 m >90 46,XY 239 5.7 122 Intermediate I Poor Poor pAML 
102 9.5 M5 52 f 8 46, XX 15.7 7.2 21 Favorable Favorable  Better pAML 
103 1.2 M5 54 m 89 46, XY, del(9)(q13q22)[8]/48, XY[16] 109.4 8.2 78 Intermediate II Intermediate Intermediate pAML 
104 4.6 M5 72 m 40 46,XY 14.5 5.3 28 Intermediate I Intermediate Intermediate sAML 
105 31.6 M5 82 m 35 n.d. 61.3 11.7 110 n.a. n.a. n.a. pAML 
106 1.5 M5 23 m 83 48,XY,+8,+13[17]/46,XY[3] 145.1 7.6 34 Intermediate II Intermediate  Poor pAML 
107 1.3 M5 58 f 70 46,XX 0.6 9.1 42 Intermediate I Poor Poor pAML 
108 0.7 M5 45 f 80 46,XX 248.1 7.3 46 Favorable Favorable Better pAML 
109 18.7 M5 53 m 85 46,XY 105.6 8.1 35 Intermediate I Poor Poor pAML 
110 7 M5 50 m 3 46, XY 27.3 11.3 85 Intermediate I Poor Poor pAML 
111 0.9 M5 54 m 96 46,XY 70.3 8.1 139 Favorable Favorable Better pAML 
Table 2. Association of OX40 Expression with genetic landscape and clinical parameters 
ELN, European LeukemiaNet classification; ELN 2017, modified European LeukimiaNet classification; CR, complete remission; pAML, de 
novo AML; tAML,therapy related AML; sAML, secondary AML evolving from MDS/MPS; FAB, French-American-British classification; PBB, 
peripheral blood blasts among nucleated cells; WBC, white blood count; Plt, platelets; HB, hemoglobin; CRP, C-reactive protein; n.s. not 
significant 
* all P values are two-sided and were calculated either with Mann-Whitney or Kruskal-Wallis test or, for categorial variables, with the chi-
square tests. 
** Correlation Spearman r 
Characteristic Analyzed Patients P Value two-sided* Cox-Regression Correlation**
PML/RARA t(15;17) 96 <0.05
RUNX1/RUNX1T1 t(8;21) 94 n.s.
CBFB/MYH11 inv(16) 93 n.s.
















age at diagnosis 110 n.s.
sex 110 n.s.
PBB [%] 109 n.s.
WBC 108 n.s
Plt[G/l] 108 n.s.
HB [g/dl] 108 n.s.
CRP [mg/dl] 108 n.s.
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